Key Takeaways
- • Lexington Partners has emerged as the lead buyer in MetLife Investment Management's secondaries transaction, acquiring a $1 billion portfolio from an $1.8 billion total portfolio shopped under Project Trident.
- • MetLife Investment Management engaged Evercore as advisor to market the $1.8 billion portfolio, demonstrating continued activity in the secondary private equity market by major institutional asset owners.
- • The deal represents a managed fund secondaries transaction, a structure where an established fund's LP positions are acquired by new investors, allowing the original portfolio company to refresh its investor base.
- • Lexington Partners' role as lead buyer underscores the firm's continued prominence in the secondaries market and its capacity to deploy capital at scale on large institutional portfolios.
Summary
The specific transaction captured involves Lexington acquiring a $1 billion tranche from the broader MetLife portfolio, representing a substantial deployment by the secondaries specialist. This managed fund structure allows MetLife Investment Management to transfer LP positions to new institutional investors while maintaining underlying portfolio exposure and generating liquidity for existing stakeholders.
The transaction reflects ongoing activity in the secondaries market, where institutional investors and established fund managers regularly refresh their investor bases through selective portfolio sales. MetLife's decision to engage an external advisor in Evercore indicates a structured, competitive process to maximize value and identify appropriate counterparties for the various portfolio components.
The deal highlights the scale at which premier secondaries investors like Lexington operate and their continued ability to attract and execute large institutional transactions. For MetLife Investment Management, the transaction provides a mechanism to optimize portfolio composition and generate capital that can be redeployed into newer or higher-conviction positions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.